Christine F. Brainson

This study shows that EZH1/2 inhibition with valemetostat enhances anti-PD1 immunotherapy in lung squamous cell carcinoma by increasing MHC Class II and reprogramming neutrophils.

This study shows that inhibiting EZH2 in lung cancer enhances immunogenicity and TIL reactivity by altering the tumor microenvironment and T cell properties.

This study shows that methionine restriction reduces lung cancer progression and enhances chemotherapy response in a mouse model and human cell lines.